Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,910 shares of the biopharmaceutical company's stock after selling 3,752 shares during the quarter. Mediolanum International Funds Ltd's holdings in Gilead Sciences were worth $5,315,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Algert Global LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $254,000. Quarry LP acquired a new stake in Gilead Sciences in the second quarter valued at approximately $43,000. Cetera Investment Advisers lifted its stake in Gilead Sciences by 1.8% in the second quarter. Cetera Investment Advisers now owns 217,702 shares of the biopharmaceutical company's stock worth $14,937,000 after acquiring an additional 3,801 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $7,847,000. Finally, Centaurus Financial Inc. increased its position in shares of Gilead Sciences by 12.4% in the 2nd quarter. Centaurus Financial Inc. now owns 4,798 shares of the biopharmaceutical company's stock valued at $329,000 after purchasing an additional 529 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on GILD. Citigroup initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Thursday, November 7th. BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. Finally, Piper Sandler boosted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $1.66 on Wednesday, reaching $99.65. 7,738,146 shares of the stock were exchanged, compared to its average volume of 7,009,158. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $124.19 billion, a PE ratio of 1,107.22, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The business has a fifty day moving average price of $92.71 and a two-hundred day moving average price of $86.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.29 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. 0.29% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.